Therapeutic Basis of Vidarabine on Adenovirus-Induced Haemorrhagic Cystitis

When adenovirus causes haemorrhagic cystitis in immunocompromised patients, vidarabine is used for its treatment because therapeutic choice is limited. Although vidarabine has been reported to be effective for these patients, its therapeutic basis has not yet been established. Vidarabine dose-depend...

Full description

Saved in:
Bibliographic Details
Published in:Antiviral chemistry & chemotherapy 2004-10, Vol.15 (5), p.281-285
Main Authors: Kurosaki, Kunikazu, Miwa, Naoko, Yoshida, Yoshihiro, Kurokawa, Masahiko, Kurimoto, Masanori, Endo, Shunro, Shiraki, Kimiyasu
Format: Article
Language:English
Subjects:
Acyclovir
Acyclovir - administration & dosage
Acyclovir - therapeutic use
Adenoviridae - drug effects
Adenoviridae - metabolism
Adenoviridae Infections - complications
Adenovirus
Adenoviruses
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiviral agents
Antiviral Agents - administration & dosage
Antiviral Agents - therapeutic use
Biological and medical sciences
Cystitis
Cystitis - drug therapy
Cystitis - etiology
Dose-Response Relationship, Drug
Hemorrhage - etiology
Hemorrhage - virology
Humans
Immunocompromised Host - drug effects
Immunocompromised hosts
Medical sciences
Metabolites
Pharmacology. Drug treatments
Protein biosynthesis
Replication
Urinary Bladder - metabolism
Vidarabine - therapeutic use
Viral Proteins - antagonists & inhibitors
Viral Proteins - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:When adenovirus causes haemorrhagic cystitis in immunocompromised patients, vidarabine is used for its treatment because therapeutic choice is limited. Although vidarabine has been reported to be effective for these patients, its therapeutic basis has not yet been established. Vidarabine dose-dependently inhibited viral replication as assessed by a yield reduction assay. Viral protein synthesis was dose-dependently inhibited by vidarabine but not at all by acyclovir, and the degree of inhibition by vidarabine was different for each of the viral proteins, ranging from 0–40% of the untreated control. These results indicated the specificity and mechanism of action of vidarabine against adenovirus. The concentration of vidarabine and its metabolite in the bladder is suggested to exhibit effective anti-adenoviral activity in suppressing the replication of adenovirus. Thus, our results support vidarabine therapy as a possible candidate for adenovirus-induced haemorrhagic cystitis in immunocompromised patients.
ISSN:2040-2066
0956-3202
2040-2066
DOI:10.1177/095632020401500507